Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | IL1B | P01584 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6217145 | 0.93 | ELANE (0.55) | ELANENPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL5758483 | 0.90 | ELANE (0.65) | ELANENPC1RAB9ANOTUMALDH1A1 | |
| SCHEMBL5757245 | 0.84 | ELANE (0.65) | ELANENPC1RAB9ASMN1; SMN2NOTUM | |
| SCHEMBL5757078 | 0.84 | NPC1 (0.44) | ELANENPC1RAB9ASMN1; SMN2NOTUM | |
| SCHEMBL11895081 | 0.84 | ELANE (0.42) | ELANENPC1RAB9ASMN1; SMN2NOTUM | |
| SCHEMBL5759522 | 0.84 | ELANE (0.61) | ELANENPC1RAB9ASMN1; SMN2NOTUM | |
| SCHEMBL5757548 | 0.83 | ELANE (0.66) | ELANESMN1; SMN2NOTUMALDH1A1KDM4E | |
| SCHEMBL5435710 | 0.83 | PLA2G10 (0.48) | ELANENPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL5757915 | 0.83 | ELANE (0.65) | ELANESMN1; SMN2NOTUMALDH1A1KDM4E | |
| SCHEMBL27624402 | 0.83 | ELANE (0.65) | ELANESMN1; SMN2NOTUMALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885NPC1 3743/4885RAB9A 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.